A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 1, 2012, Pages 191-199

  Abbas, Richat ^a   Hug, Bruce A ^a   Leister, Cathie ^a   Sonnichsen, Daryl ^a  

^a PFIZER INC   (United States)

Author keywords

Diarrhea; Dose regimen; ErbB2 inhibitor; Healthy subjects; Pharmacokinetics

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; HEMOGLOBIN; LACTOFERRIN; NERATINIB; PLACEBO;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ANOREXIA; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; FATIGUE; FECES ANALYSIS; FEMALE; FLATULENCE; GENOTYPE; HEADACHE; HEMATOCHEZIA; HEMOGLOBIN DETERMINATION; HOT FLUSH; HUMAN; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; MELENA; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; OUTCOME ASSESSMENT; PH MEASUREMENT; PHARYNGITIS; PRESYNCOPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SKIN IRRITATION; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FECES; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTOFERRIN; METABOLIC CLEARANCE RATE; NEOPLASM PROTEINS; QUINOLINES; RECEPTOR, ERBB-2; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84863492225     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1857-3     Document Type: Article

References (34)

1. Gutierrez C, Schiff R (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135:55-62
2. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820 (Pubitemid 43290919)
3. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez RP, Piccart-Gebhart MJ (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29-36 (Pubitemid 46039831)
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 344:783-792 (Pubitemid 32222155)
5. HERCEPTIN® (2009) (Trastuzumab) Intravenous infusion [package insert]. Genentech Inc, South San Francisco, CA
6. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22:1063-1070 (Pubitemid 41095039)
7. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, Danese S, Vietti-Ramus G, Durando A, Venturini M, Aglietta M (2006) Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11:318-324
8. Rabindran SK (2005) Antitumor activity of HER-2 inhibitors. Cancer Lett 227:9-23
9. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou HR, Wang YF, Wissner A (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64:3958-3965 (Pubitemid 38697310)
10. Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK, Shen R, Shi X, Wang YF, Upeslacis J, Wissner A (2005) Optimization of 6,7-disubstituted-4- (arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 48:1107-1131 (Pubitemid 40270454)
11. Paridaens R, Badwe R, Sun Y, Dirix L, Cardoso F, Powell C, Zacharchuk C, Burstein HJ (2009) Neratinib (HKI-272), an irreversible pan erbB2 + receptor tyrosine kinase inhibitor: phase 2 results in patients with erbB2 + advanced breast cancer. Ann Oncol 20:ii61, Abstract 186P
12. Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Janne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA (2009) A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15:2552-2558
13. Chow L, Jiang Z, Epstein R, Bondarenko I, Awada A, Coughlin C, Gauthier E, Zhao Y, Abbas R, Hershman D (2009) Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors. J Clin Oncol 27:160s, Abstract 3557
14. Swaby R, Blackwell K, Jiang Z, Sun Y, Dieras V, Zaman K, Zacharchuk C, Powell C, Abbas R, Thakuria M (2009) Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. J Clin Oncol 27:1004
15. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, Badwe R (2010) Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
17. Thatcher N, Chang A, Parikh P, Rodrigues PJ, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer). Lancet 366:1527-1537 (Pubitemid 41540110)
18. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130
19. Abbas R, Hug B, Leister C, Burns J, Sonnichsen D (2009) Single-ascending-dose study of safety, tolerability, and pharmacokinetics of neratinib (HKI-272) in healthy subjects. AAPS J 11(S2)
20. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D (2011) Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 71:522-527
21. Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32:920-924 (Pubitemid 27382038)
22. Jusko WJ (1992) Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics: principles of therapeutic drug monitoring. Applied Therapeutics, Spokane, pp 2-43
23. Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, Bates SE (2002) Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 1:696-702
24. Cha PC, Mushiroda T, Zembutsu H, Harada H, Shinoda N, Kawamoto S, Shimoyama R, Nishidate T, Furuhata T, Sasaki K, Hirata K, Nakamura Y (2009) Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet 54:572-580
25. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98:1739-1742 (Pubitemid 44942712)
26. de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, Sparreboom A (2007) Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 81:42-49 (Pubitemid 46050866)
27. (2007) TYKERB® (lapatinib) tablets [package insert]. Glaxo-SmithKline, Research triangle park
28. (2005) Iressa® (gefitinib tablets) [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington
29. (2004) Tarceva® (erlotinib tablets) [package insert]. Genentech, Inc, South San Franscisco
30. Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC (2010) Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3076-3083
31. Ross HJ, Blumenschein GR Jr, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA (2010) Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 16:1938-1949
32. Uribe JM, Gelbmann CM, Traynor-Kaplan AE, Barrett KE (1996) Epidermal growth factor inhibits Ca(2 +)-dependent Cl- transport in T84 human colonic epithelial cells. Am J Physiol 271:C914-C922
33. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119-1127
34. de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, McLeod HL (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10:5889-5894 (Pubitemid 39180970)